ROCKVILLE, Md., Oct. 31,
2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the
"Company"), a US-based, global biotech company, exclusively focused
on the development of highly differentiated immunotherapies for the
treatment of cancer, today announced that it plans to release
financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern
Time.
The Company will not host a conference call to discuss its third
quarter 2024 financial results. The Company intends to host an
investor update call in conjunction with its 2024 full-year
financial results to discuss its clinical pipeline, corporate
strategy, and objectives. Information about financial results,
conference calls, webcasts, and other information is posted on the
Company's website.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global biotech company,
exclusively focused on the development of highly differentiated
immunotherapies for the treatment of cancer.
I-Mab has established operations in Rockville, Maryland, and Short Hills, New
Jersey. For more information, please
visit https://www.i-mabbiopharma.com and follow us
on LinkedIn and X.
I-Mab Investor & Media Contacts
Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/i-mab-to-release-q3-2024-financial-results-on-november-14-2024-302292364.html
SOURCE I-Mab Biopharma